啟明醫療(02500.HK)委任MARTIN B. LEON教授擔任RDN創新器械全球首要研究者
啟明醫療(02500.HK)公布,已委任Martin B. Leon教授為控股子公司Renaly開發的新一代去腎交感神經術(RDN)創新器械的全球首要研究者。董事會相信憑借Martin教授在該領域的豐富經驗,公司RDN創新器械將在臨床上快速推進。
Renaly所開發的新一代RDN器械,其獨有的雙模態超聲技術平台,可實現具備實時監測功能的非接觸性連續消融治療,在進行精準高效消融的同時顯著降低由於消融不可控帶來的諸如神經消融不充分或血管損傷等問題的發生,最終提升手術的安全性和有效性。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.